|
Bacteria | Cells | MOI (bacteria : cells) | Extracellular matrix | Growth medium | Days | Year | Reference |
|
M. tuberculosis and M. bovis | Human PBMCs | 1 : 150 | Agarose coated 96-well tissue culture plates | RPMI-1640, 100 U/mL penicillin G, 100 μg/mL streptomycin, and 10% FCS | 7 | 2003 | [60] |
|
M. tuberculosis | Human PBMCs and autologous macrophages (1 : 1) | 1 : 4–40 for host cell cytokine production | Ultralow attachment 24-well tissue culture plates | RPMI-1640, 10% human serum | 9 | 2007 | [61] |
|
M. tuberculosis | Human PBMCs and autologous macrophages (1 : 1), extra nonadherent PBMCs added at 2 and 5 days | 1 : 400–4000 for histology and immunostaining | Ultralow attachment 24-well tissue culture plates | RPMI-1640, 10% human serum | 9 | 2007 | [61] |
|
M. tuberculosis | Human PBMCs | 1 : 10 | 0.95 mL collagen solution, 50 μL 10xDPBS, 4 μL fibronectin, 10 μL 1 N NaOH | RPMI-1640, 20% human serum | 8 | 2013 | [62] |
|
M. leprae | Human macrophages and autologous PBMCs (1 : 5) | 50 : 1 | 24-well tissue culture plates | RPMI-1640, 20% FCS | 10 | 2013 | [63] |
|
M. bovis | Human PBMCs | 1 : 10 | 24-well tissue culture plates | RPMI-1640, 10% human serum, 300 U/mL penicillin, 0.3 mg/mL streptomycin | 15 | 2004 | [64] |
|
M. avium subsp paratuberculosis | Bovine PBMCs | 1 : 8 and 1 : 16 | 0.95 mL bovine collagen solution, 50 μL 10xDPBS, 4 μL fibronectin (1 mg/mL), 10 μL 1 N NaOH | RPMI-1640, 100 U/mL penicillin G, 100 μg/mL streptomycin, 20% FBS | 10 | 2014 | Current report |
|